Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Trial Profile

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Gallium 68-DOTATOC (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use
  • Most Recent Events

    • 15 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 14 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top